Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer

Pancreatic cancers occurring in carriers of a pathogenic germline alteration in BRCA1/2 (gBRCA1/2) are assumed to demonstrate homologous recombination repair deficiency (HRD), associated with sensitivity to platinum-based chemotherapy and synthetic lethality with PARP inhibitors (PARPi). However, pr...

Descripción completa

Detalles Bibliográficos
Autor principal: Lowery, Maeve A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000729/
https://www.ncbi.nlm.nih.gov/pubmed/31787750
http://dx.doi.org/10.1038/s41416-019-0645-9
_version_ 1783494095767863296
author Lowery, Maeve A.
author_facet Lowery, Maeve A.
author_sort Lowery, Maeve A.
collection PubMed
description Pancreatic cancers occurring in carriers of a pathogenic germline alteration in BRCA1/2 (gBRCA1/2) are assumed to demonstrate homologous recombination repair deficiency (HRD), associated with sensitivity to platinum-based chemotherapy and synthetic lethality with PARP inhibitors (PARPi). However, primary and secondary resistance to these agents occurs even in this highly selected population.
format Online
Article
Text
id pubmed-7000729
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70007292020-12-02 Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer Lowery, Maeve A. Br J Cancer Editorial Pancreatic cancers occurring in carriers of a pathogenic germline alteration in BRCA1/2 (gBRCA1/2) are assumed to demonstrate homologous recombination repair deficiency (HRD), associated with sensitivity to platinum-based chemotherapy and synthetic lethality with PARP inhibitors (PARPi). However, primary and secondary resistance to these agents occurs even in this highly selected population. Nature Publishing Group UK 2019-12-02 2020-02-04 /pmc/articles/PMC7000729/ /pubmed/31787750 http://dx.doi.org/10.1038/s41416-019-0645-9 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Editorial
Lowery, Maeve A.
Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
title Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
title_full Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
title_fullStr Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
title_full_unstemmed Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
title_short Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
title_sort genotype–phenotype correlation in brca1/2 mutation-associated pancreatic cancer
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000729/
https://www.ncbi.nlm.nih.gov/pubmed/31787750
http://dx.doi.org/10.1038/s41416-019-0645-9
work_keys_str_mv AT lowerymaevea genotypephenotypecorrelationinbrca12mutationassociatedpancreaticcancer

Ejemplares similares